The ISR Immunolide Platform Expanded into Hepatitis B

Screenings of the substances from ISR’s Immunolide platform have identified a new pharmaceutical lead candidate, ISR051, which has immune stimulating effects, apparently advantageous in the treatment of hepatitis B. ISR now plans to expand its research and development portfolio to encompass, apart from HIV, tuberculosis and cancer, also hepatitis B.The hepatitis B virus (HBV) is one of the world’s most ubiquitous diseases, where WHO estimates over two billion people have or have had the disease and 240 million are chronic bearers. Nearly 700,000 people die in this disease every year, and 25%